ETRM: Post FDA Approval of the VBLOC® vagal blocking therapy, delivered via the Maestro® System for the treatment of Obesity. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years.
12/23: Purchased speculative position @ 1.42 in anticipation of FDA decision based on FDA Review Panel votes, Analyst Recommendations, and targeted DD
12/31: Short Interest Outstanding- 6,843,496
01/14: EnteroMedics Announces FDA Approval of VBLOC® Vagal Blocking Therapy for the Treatment
01/14: 20,658,470 shares traded volume and 2,866,558 shares traded short volume
01/14: Sold 70% holdings @ 2.02 for +40% gain (opportunity cost: 3 weeks)
01/15: 5,512,037 shares traded volume and 716,077 shares traded short volume
01/16: Holding 30% initial speculative position
01/16: MV of shares @ 1.30
~Performing full DD and risk analysis for preparation for HTM